Investors & News Esther Kwak 6/20/26 Esther Kwak 6/20/26 Mezzion Pharma Completes FUEL-2 Phase 3 Regulatory Milestone Read More Esther Kwak 6/20/26 Esther Kwak 6/20/26 Mezzion Secures Strategic Financing to Support Advancement of Global Phase 3 FUEL-2 Trial in Fontan Patients Read More Esther Kwak 6/20/26 Esther Kwak 6/20/26 Mezzion Reports Pre-IND FDA Feedback on the Development of Udenafil in ADPKD Read More Elli Park 4/16/25 Elli Park 4/16/25 New ICD-10 Codes Recognize Fontan-Associated Conditions, Advancing Care and Coverage for Rare Congenital Heart Disease Community - PR Newswire Read More Elli Park 12/26/23 Elli Park 12/26/23 The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation - ScienceDirect Read More Veronica Oronos 4/24/23 Veronica Oronos 4/24/23 Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients - PR Newswire Read More Veronica Oronos 2/20/23 Veronica Oronos 2/20/23 Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects - PR Newswire Read More Veronica Oronos 5/30/22 Veronica Oronos 5/30/22 Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease - PR Newswire Read More
Esther Kwak 6/20/26 Esther Kwak 6/20/26 Mezzion Pharma Completes FUEL-2 Phase 3 Regulatory Milestone Read More
Esther Kwak 6/20/26 Esther Kwak 6/20/26 Mezzion Secures Strategic Financing to Support Advancement of Global Phase 3 FUEL-2 Trial in Fontan Patients Read More
Esther Kwak 6/20/26 Esther Kwak 6/20/26 Mezzion Reports Pre-IND FDA Feedback on the Development of Udenafil in ADPKD Read More
Elli Park 4/16/25 Elli Park 4/16/25 New ICD-10 Codes Recognize Fontan-Associated Conditions, Advancing Care and Coverage for Rare Congenital Heart Disease Community - PR Newswire Read More
Elli Park 12/26/23 Elli Park 12/26/23 The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation - ScienceDirect Read More
Veronica Oronos 4/24/23 Veronica Oronos 4/24/23 Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients - PR Newswire Read More
Veronica Oronos 2/20/23 Veronica Oronos 2/20/23 Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects - PR Newswire Read More
Veronica Oronos 5/30/22 Veronica Oronos 5/30/22 Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease - PR Newswire Read More
